Please assess the completion status of the following clinical trial:

Trial Title: Ketamine For Suicidal Ideation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking Male or female patients, 18-80 years~* Patients have voluntarily admitted themselves to an inpatient psychiatric unit at MSH or, regarding the outpatient population, have clinically significant suicidal ideation without intent to harm themselves~* Women of childbearing potential must have a negative pregnancy test~* Clinically significant suicidal ideation and score of ≥4 on MADRS item 10 for suicidality~* Each subject must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent document~Exclusion Criteria:~* Lifetime history of schizophrenia or other primary psychotic disorder~* Current presence of psychotic symptoms~* Lifetime history of a clearly established psychotic episode~* Established diagnosis of Schizoid, Schizotypal or Paranoid personality disorder~* Urine toxicology screen positive for drugs of abuse on admission~* Substance abuse or dependence within the preceding 1 month~* Anticipated discharge within 7 days of study enrollment (for patients in the inpatient arm)~* Women who plan to become pregnant, are pregnant or are breast-feeding~* Concurrent course of electroconvulsive therapy (ECT)~* Any unstable medical illness including hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease~* Clinically significant abnormal findings of laboratory parameters, physical examination, or ECG~* The presence of any known or suspected contraindications to midazolam or ketamine including, but not limited to, known allergic reactions to these agents or acute intermittent porphyria~* Uncontrolled hypertension, defined as BP systolic \>160 or BP diastolic \>100 on medications~* Arrhythmia requiring medication~* Severe coronary artery disease, defined as Canadian Cardiovascular Status III or IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): single dose IV ketamine, .5mg/kg
- Midazolam (Type: PLACEBO_COMPARATOR): single dose IV midazolam, .45mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).